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Abstract. 
 
The cytoskeleton-membrane linker protein
ezrin has been shown to associate with phosphatidyl-
 
inositol 4,5-bisphosphate (PIP
 
2
 
)-containing liposomes
via its NH
 
2
 
-terminal domain. Using internal deletions
and COOH-terminal truncations, determinants of PIP
 
2
 
binding were located to amino acids 12–115 and 233–
310. Both regions contain a KK(X)
 
n
 
K/RK motif con-
served in the ezrin/radixin/moesin family. K/N muta-
 
tions of residues 253 and 254 or 262 and 263 did not
affect cosedimentation of ezrin 1-333 with PIP
 
2
 
-con-
taining liposomes, but their combination almost com-
pletely abolished the capacity for interaction. Similarly,
double mutation of Lys 63, 64 to Asn only partially re-
duced lipid interaction, but combined with the double
mutation K253N, K254N, the interaction of PIP
 
2 
 
with
ezrin 1-333 was strongly inhibited. Similar data were
obtained with full-length ezrin. When residues 253, 254,
262, and 263 were mutated in full-length ezrin, the in
vitro interaction with the cytoplasmic tail of CD44 was
not impaired but was no longer PIP
 
2
 
 dependent. This
construct was also expressed in COS1 and A431 cells.
Unlike wild-type ezrin, it was not any more localized to
dorsal actin-rich structures, but redistributed to the cy-
toplasm without strongly affecting the actin-rich struc-
tures. We have thus identiﬁed determinants of the PIP
 
2
 
binding site in ezrin whose mutagenesis correlates with
an altered cellular localization.
Key words: cytoskeleton • actin • CD44 • A431 cells •
COS1 cells
 
Introduction
 
Members of the ezrin/radixin/moesin (ERM)
 
1
 
 family and
the related tumor suppressor merlin are part of the protein
4.1 superfamily. They are defined as cytoskeleton-mem-
brane linkers (for reviews, see Bretscher, 1999; Mangeat et
al., 1999). The anchorage of the ERM family to the plasma
membrane occurs in different ways. Indirect binding of
ERM to different proteins with several transmembranous
domains, such as the cystic fibrosis transmembrane con-
ductance regulator (Short et al., 1998) or the Na
 
1
 
/H
 
1
 
 anti-
porter (Murthy et al., 1998; Yun et al., 1998), involves an
adaptor protein such as EBP 50 (Reczek et al., 1997).
ERM can also be linked to the cytoplasmic tail of mem-
brane proteins with a single transmembranous domain
such as CD43, CD44, I-CAM 1, I-CAM 2, and I-CAM 3.
These interactions appear to be facilitated by the phos-
pholipid phosphatidylinositol 4,5-bisphosphate (PIP
 
2
 
) (Hi-
rao et al., 1996; Serrador et al., 1997; Yonemura et al.,
1998). It is not clear whether this dependency is due to a
requirement for PIP
 
2 
 
of the transmembranous protein or
of the ERM itself (Hirao et al., 1996; Heiska et al., 1998).
Some studies suggest that PIP
 
2
 
 could help unmask cryptic
binding sites in ERM. PIP
 
2
 
 could thus be involved in the
activation process of the ERM, switching the inactive
“dormant” molecule to an activated state (Matsui et al.,
1999; Nakamura et al., 1999). ERM could also directly in-
teract with PIP
 
2
 
-containing phospholipid bilayers (Niggli
et al., 1995; Hirao et al., 1996; Heiska et al., 1998). Thus,
the direct association of ezrin with PIP
 
2
 
 and also with the
p85 subunit of the phosphatidylinositol 3-kinase may pro-
vide a mechanism to anchor the enzyme in proximity to its
substrate (Gautreau et al., 1999).
Talin, another member of the 4.1 family, has been shown
to insert into bilayers of liposomes containing acidic phos-
pholipids using hydrophobic photolabeling. Lipid interac-
 
tion was attributed to a 47 kD NH
 
2
 
-terminal domain (Nig-
gli et al., 1994). Similarly, we have demonstrated that the
NH
 
2
 
-terminal domain of ezrin (amino acids 1–309) was
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necessary and sufficient for interaction with PIP
 
2
 
-contain-
ing liposomes. We showed that ezrin binds preferentially
to liposomes containing PIP
 
2
 
 as compared with other phos-
pholipids such as phosphatidylserine, and that this interac-
tion occurs at physiological ionic strength. Under these
conditions, ezrin discriminates between PIP
 
2
 
, phospha-
tidylinositol 4-monophosphate, and phosphatidylinositol
(Niggli et al., 1995).
In this study, we further characterized the interaction of
the NH
 
2
 
-terminal domain of ezrin with PIP
 
2
 
-containing lipo-
somes by truncation and site-directed mutagenesis. Amino
acids that are involved in binding to PIP
 
2
 
-containing lipo-
somes have been identified. They are located in two distinct
regions of this domain. Similarly, PIP
 
2
 
 interaction was abol-
ished when the same critical mutations were introduced in
the full-length ezrin molecule. Although the PIP
 
2
 
-indepen-
dent interaction of ezrin with proteins was not affected, its
intracellular localization was drastically changed. Expression
of the mutated first 310 amino acids of ezrin led to a loss of
the ability of the NH
 
2
 
-terminal domain of ezrin to promote
cell extensions (Martin et al., 1997; Amieva et al., 1999).
 
Materials and Methods
 
Site-directed Mutagenesis
 
The preparation of constructs with internal deletions as well with COOH-ter-
minal truncations has already been described (Roy et al., 1997)
 
.
 
 The number-
ing of the amino acid sequence of ezrin includes the first methionine, corre-
sponding to the protein expressed in bacteria. The quick change site-directed
mutagenesis kit from Stratagene was used. The changed bases are underlined.
The oligonucleotides (sense) (5
 
9
 
–3
 
9
 
) used for introducing the K63N mutation
in pGEX-2T ezrin 1-586 were GGCTGAAGCTGGATAATAAGGT-
GTCTGCCCAGG (12 cycles, 95
 
8
 
C, 30 s; 55
 
8
 
C, 1 min; 68
 
8
 
C, 15 min) and
GGAACATCTCTTTCAATGACAATAATTTTGTCATTAAACCC for
K253N, K254N (16 cycles, 95
 
8
 
C, 30 s; 50
 
8
 
C, 1 min; 68
 
8
 
C, 14 min). The follow-
ing oligonucleotides were used to mutate the pGEX-2T ezrin 1-333:
GGCTGAAGCTGGATAATAATGTGTCTGCCCAGGAGG (K63N,
K64N), GTCATTAAACCCATCGACAATAATGCACCTGACTTT-
GTG (K262N, K263N) and GCTGGATAAGAAGGTGGCTGCCCAG-
GAGGTCAGG (S66A). For this later series, 14 cycles were performed (95
 
8
 
C,
30 s; 55
 
8
 
C, 1 min; 68
 
8
 
C, 12 min). The K63N mutation was introduced in the
pGEX-2T ezrin 1-333 vector by excising the XmaI/AatII fragment of pGEX
ezrin 1-333 and cloning this fragment in the pGEX-2T ezrin 1-586 K63N de-
leted from its XmaI/AatII fragment. The K253N, K254N, K262N, and K263N
mutations were introduced in the pGEX-2T ezrin 1-333 K63,64N vector after
purification of the inserts Cfr9I/KpnI containing the indicated mutations. The
K253N, K254N, K262N, and K263N mutations were introduced in pGEX-2T
ezrin 1-586 after excising the Asp718/Cfr9I fragment from pGEX-2T ezrin
1-333 and ligation in the similarly cut recipient vector. The K63N, K64N,
K253N, K254N, K262N, and K263N mutations from pGEX-2T ezrin 1-333
K63N, K64N, K253N, K254N, K262N, and K263N were introduced in
pGEX-2T  ezrin 1-586 after excising the NcoI/Cfr9I fragment. For transfection
experiments, the K253N, K254N, K262N, and K263N mutations were intro-
duced into the pCB6 vesicular stomatitis virus glycoprotein G (VSV-G)–
tagged plasmid encoding for the wild-type ezrin, a kind gift of Dr. Monique
Arpin (Curie Institute, Paris, France) (Algrain et al., 1993). The similarly mu-
tated ezrin 1-310 tagged with the VSV-G peptide was derived from the above
construct using appropriate restriction enzymes. All constructs were se-
quenced using the T7 Sequenase version 2.0 (Amersham Pharmacia Biotech).
Plasmid (pSR CD44) encoding the full-length CD44 protein was ob-
tained from R. Lamb (MRC, London, UK). The region coding for the cyto-
plasmic tail of the protein (amino acids 291–360) was amplified by poly-
merase chain reaction using the Pfu polymerase (Stratagene) and subcloned
in the BamHI/EcoRI site of the pGEX-2T vector. The vector encoding the
amino acids 329–358 of EBP50 in fusion with glutathione S-transferase
(GST) was provided by A. Bretscher (Cornell University, Ithaca, NY).
 
Protein Expression and Purification
 
After an overnight culture in LB medium (Luria Broth) at 37
 
8
 
C, protein
expression was induced with 0.5 mM isopropyl 
 
b
 
-
 
D
 
-thiogalactopyranoside
 
for 45 min (NH
 
2
 
-terminal constructs) or 1 h (full-length ezrin). The fol-
lowing conditions are given for a 1 liter culture scale and all steps were
performed at 4
 
8
 
C. Bacteria were pelleted at 5,000 
 
g
 
, resuspended in 15 ml
PBS containing protease inhibitors (Complete; Boehringer) and sonicated
three times for 2 min with pulses for 50% of the time. The sonicated bac-
teria were diluted to 30 ml with PBS, centrifuged for 30 min at 17,000 
 
g,
 
and the supernatant was diluted to 50 ml. Glutathione-agarose (1.5 ml gel)
was added to the supernatant and left on a rotary shaker. For NH
 
2
 
-termi-
nal constructs, fusion proteins were allowed to adsorb on the gel over-
night. The slurry was then poured in a column and washed with PBS. Fur-
ther washing of the column was carried out with Tris-HCl, pH 7.4, and 100
mM NaCl. Nucleic acids bound on the fusion protein were then degraded
by adding 150 U benzonase and 50 
 
m
 
g RNase after an incubation at room
temperature for 90 min. After washing the column, the same buffer, but
containing 2.5 mM CaCl
 
2
 
, was added together with 5 IU thrombin and the
cleavage was allowed to process for 90 min. The protein was recovered in
the eluate and the thrombin action was stopped with para-aminobenzami-
dine beads (Sigma-Aldrich).
For full-length ezrin constructs, the fusion proteins were allowed to ad-
sorb on the glutathione agarose gel for 2 h. The gels were poured in a col-
umn and washed sequentially with PBS and Tris-HCl, pH 8.0. After glu-
tathione elution (10 mM), full-length ezrin was dialyzed overnight against
a buffer containing 20 mM Tris-HCl, pH 7.4, 0.1 mM EDTA, and 15 mM
mercaptoethanol
 
. 
 
50 mM NaCl and 2.5 mM CaCl
 
2
 
 were added
 
 
 
to the di-
alysate. Digestion with thrombin was allowed to proceed for 90 min at
37
 
8
 
C. Samples were diluted twice with FPLC buffer A (25 mM MES, pH
6.2, 20 mM NaCl, and 0.01% mercaptoethanol). Elution from the mono-Q
column of wild-type ezrin as well as of ezrin with mutations K253N,
K254N, K262N, and K263N occurred at 65 mM NaCl, that of ezrin with
mutations K63N, K64N, K253N, K254N, K262N, and K263N at 85 mM
NaCl. All proteins were stored at 4
 
8
 
C in the presence of 0.05% NaN
 
3
 
.
The cytoplasmic tail of CD44 and the EBP50 fragment were obtained
using procedures similar to that used for ezrin full-length constructs, ex-
cept that the fusion proteins were not eluted from the glutathione agarose
gel. The adsorbed GST-CD44 protein was kept at 4
 
8
 
C and used within
24 h after preparation.
 
Determination of Protein Concentration
 
The UV spectra were recorded and the protein concentration was calcu-
lated from the absorption coefficients at 220 and 280 nm. The Bradford
assay (Bradford, 1976) did not allow a quantitative estimation of the pro-
tein content because of the peculiar amino acid composition of the NH
 
2
 
-
terminal constructs; this assay was used only for comparing relative
amounts of the protein.
 
Phospholipids
 
Phosphatidylcholine (PC) and PIP
 
2
 
 were obtained from Lipid Products.
For some experiments, PIP
 
2
 
 was also obtained from Sigma-Aldrich. No
difference was detected between the two products.
 
Cosedimentation of Ezrin and Ezrin Constructs with 
Lipid Vesicles
 
Analysis of protein–lipid interactions by cosedimentation of proteins with
large multilamellar liposomes has been documented in detail elsewhere
(Niggli et al., 1994). Large, multilamellar liposomes were prepared from
PC and PIP
 
2
 
 in a buffer containing 20 mM Hepes, pH 7.4, 0.2 mM EGTA
as described (Niggli et al., 1995). Ezrin, and ezrin constructs (dialyzed after
purification against a buffer containing 20 mM Tris/HCl, pH 7.4, 0.1 mM
EDTA, 15 mM mercaptoethanol) were centrifuged before the experi-
ments for 20 min at 20,000 
 
g
 
, 4
 
8
 
C, followed by protein determination. Pro-
teins were subsequently incubated for 15 min at 22
 
8
 
C in the presence of
130 mM KCl and in the absence of liposomes, followed by a further incu-
bation in the absence or presence of liposomes for 15 min. In part of the
experiments, proteins were not dialyzed after purification, and lipid inter-
actions of ezrin constructs were assayed directly in the buffer in which the
protein was recovered after column chromatography. In this case, EGTA
was added to the protein solution to neutralize Ca
 
2
 
1
 
, which interferes with
the liposome cosedimentation assay (see Results). This resulted in a pro-
tein solution containing (mM): 50 Tris/HCl, pH 7.4, 100 NaCl, 1.25 CaCl
 
2
 
,
2.8 EGTA, and 0.05% NaN
 
3
 
. No difference in lipid interaction of the same
preparation of wild-type ezrin domains could be detected when proteins
were added to the lipids before or after dialysis provided that Ca
 
2
 
1
 
 was
neutralized by EGTA. Proteins were kept under nitrogen during incuba-
tion with lipids. Final concentrations of protein were 27.5–55 
 
m
 
g/ml and of 
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lipid 0.5 mg/ml. The fraction of wild-type ezrin (1-333) cosedimenting with
PIP
 
2
 
-containing liposomes was similar for both protein concentrations
 
.
 
The mixtures were subsequently centrifuged for 30 min at 100,000 
 
g
 
, 4
 
8
 
C.
The pellets were solubilized in 50–100 
 
m
 
l sample buffer (Niggli et al.,
1994). The supernatants were mixed with the corresponding amount of the
threefold concentrated sample buffer. After heating the samples for 5–10
min at 95
 
8
 
C, they were applied to SDS-polyacrylamide gradient gels (Nig-
gli et al., 1995). The amount of protein present in pellets and supernatants
was quantified by scanning the bands of the Coomassie blue-stained gels.
The amount of ezrin sedimented in the absence of liposomes was always
subtracted from that sedimenting in the presence of lipid (
 
5
 
 specific
cosedimentation). In a series of representative experiments, 22 
 
6 
 
8% (
 
n 
 
5
 
10) of wild-type ezrin 1-333 sedimented in the absence of lipid. Compara-
ble data were obtained for mutated proteins. The amount of wild-type
ezrin 1-333 recovered in the pellet was increased in the presence of lipo-
somes containing 20% PIP
 
2
 
 to 77 
 
6 
 
9% (
 
n 
 
5
 
 10) of total protein. The spe-
cific cosedimentation of wild-type ezrin 1-333 corresponds thus to 300 
 
6
 
160% (
 
n 
 
5
 
 10) of the amount of protein sedimenting in the absence of
lipid. Some variations were observed in the extent of cosedimentation with
liposomes when comparing different protein preparations, possibly due to
variable denaturation during purification and/or storage.
The data are given as mean 
 
6
 
 
 
SD of 
 
n
 
 experiments. Differences be-
tween data were analyzed with the Student’s 
 
t
 
 test for paired data, with a
 
P
 
 
 
,
 
 
 
0.05 considered significant.
 
Interaction of Ezrin with the Cytoplasmic Tail of CD44
 
GST or GST-CD44 (5 
 
m
 
g, 10 
 
m
 
l) bound to glutathione agarose beads were
equilibrated in the reaction buffer (25 mM Tris-HCl, pH 7.4, 150 mM KCl,
1 mM MgCl
 
2
 
, and 1 mM DTT). PIP
 
2
 
 was added in micellar form (Hirao et
al., 1996). Full-length wild-type ezrin or ezrin K253N, K254N, K262N, and
K263N (3.5 
 
m
 
g, 1 
 
m
 
M) were incubated in a final volume of 50 
 
m
 
l with
beads for 1 h at room temperature. Beads were then washed three times
with 500 
 
m
 
l buffer at 4
 
8
 
C. After the final wash, 20 mM glutathione was
added for 1 h. Aliquots of the supernatant were then analyzed by SDS-
PAGE and Western blotting for the presence of ezrin using procedures
described in Roy et al. (1997).
 
Homotypic Interaction Assay
 
Wild-type ezrin 1-586 was coated in wells of a microtiter plate and residual
binding sites saturated with 2% bovine serum albumin (Roy et al., 1997).
Ezrin 1-333 constructs (0.5 
 
m
 
M each) were then added in buffer (20 mM
Tris-HCl, pH 7.4, 5 mM MgCl
 
2
 
, 100 mM KCl, and 0.2 mM dithiothreitol).
After 1 h of incubation, wells were rinsed with the same buffer and sam-
ples were processed for SDS-PAGE analysis and Western blotting.
 
Intrinsic Tryptophane Fluorescence Measurements
 
Fluorescence spectra were recorded with an Aminco-Bowman Series 2 lu-
minescence spectrometer at 30
 
8
 
C. Protein samples were incubated in 50
mM Tris-HCl, pH 7.4, 100 mM NaCl. The tryptophane emission fluores-
cence spectrum was recorded by excitation at 292 nm. Both excitation and
emission beams were set at 2-nm bandwidth.
 
Cell Culture and Transient Transfection
 
COS1 and A431 cells were maintained in DMEM containing 10% FBS.
Cells were seeded 24 h before transfection at a density of 200,000 cells per
35-mm dish. Transfection of plasmids into COS1 cells was carried out by
using Effectene (Qiagen) as recommended by the manufacturer (0.4 
 
m
 
g
plasmid in 100 
 
m
 
l EC buffer and 3.2 
 
m
 
l enhancer for 5 min at room tem-
perature, then addition of 10 
 
m
 
l Effectene followed by contact with cells
10 min later). Superfect (QIAGEN) was used for transfection of A431
cells: 2 
 
m
 
g DNA was mixed with 100 
 
m
 
l DMEM and 10 
 
m
 
l Superfect for 5
min at room temperature before addition to cells. The medium was
changed 3 h later. Immunofluorescence and cell fractionation were carried
out 30 and 42 h after transfection, respectively.
 
Cell Fractionation
 
The cells were washed twice with PBS with 0.5 mM MgCl
 
2
 
 and 2 mM
CaCl
 
2
 
. Lysis buffer [(mM) 10 Hepes, pH 7.4, 2.5 MgCl
 
2
 
, 1 EGTA, 1
EDTA, 1 vanadate, 10 NaF, 0.1 PMSF, 100 
 
m
 
g/ml CHAPS, 10% glycerol,
and a cocktail of antiproteases] was added (300 
 
m
 
l per 35-mm dish). Cells
were scraped off with a rubber policeman and homogenized by 20 strikes
in a Dounce homogenizer (pestle B). The homogenates were centrifuged
at 25,000 
 
g
 
 for 30 min at room temperature. The supernatant corresponds
to the cytosolic fraction. The pellet was resuspended in 300 
 
m
 
l buffer A
[(mM) 50 MES, pH 6.4, 2.5 MgCl
 
2
 
, 1 EGTA, 1 vanadate, 10 NaF, 10%
glycerol, 0.5% Triton X-100, antiprotease cocktail] and centrifuged at
18,000 
 
g
 
 for 15 min at 4
 
8
 
C. The pellet (Triton X-100 nonextractable mate-
rial) was resuspended in 300 
 
m
 
l buffer A and sonicated. Fractions (30 
 
m
 
l)
were applied to SDS-polyacrylamide gels and immunoblotted with P5D4
anti–VSV-G mAb or anti-ezrin antibodies (Andréoli et al., 1994; Roy et
al., 1997). Anti-ezrin antibodies generated either against the full-length
protein or the first 310 residues were defined as anti–C and –N antibodies,
respectively (Andréoli et al., 1994).
 
Immunofluorescence Analysis
 
Cells were fixed with 3.7% formaldehyde in PBS for 20 min and treated with
TBS containing 0.2% Triton X-100 for 4 min. Cells were incubated with anti–
VSV-G mAb (clone P5D4; Kreis, 1986) for 1 h at room temperature, washed,
and incubated with FITC-conjugated phalloidin and Texas red–conjugated
anti–mouse Ig Ab (Sigma-Aldrich). After final washes and mounting in
Mowiol, cells were examined using a laser scanning confocal microscope
(Leica or Bio-Rad Laboratories) using a 63
 
3 
 
1.4 oil immersion objective.
 
Results
 
Mapping of the PIP2 Binding Site
Association of ezrin with the lipid bilayer was first studied
with fusion proteins corresponding to the NH2-terminal
domain of ezrin, a region which has been previously shown
to mediate the interaction of ezrin with PIP2-containing li-
posomes (Niggli et al., 1995). As a measure for bilayer as-
sociation, cosedimentation of proteins with large lipo-
somes containing 20% PIP2 and 80% PC was analyzed.
Control values of protein sedimenting in the absence of
lipid were always subtracted. Lipid interactions were mea-
sured under physiological ionic strength conditions. We
have found previously that addition of 1 mM MgCl2 (in the
presence of 60 mM EGTA and 50 mM EDTA) markedly
reduced cosedimentation of wild-type full-length ezrin
with PIP2-containing liposomes by 40–70% (data not
shown). According to Flanagan et al. (1997), divalent cat-
ions promote fusion of PIP2 micelles into insoluble aggre-
gates and may thus also adversely affect PIP2-containing
liposomes. All the experiments were therefore carried out
in the absence of added divalent cations.
Figure 1. Effects of truncations and internal deletions on the
cosedimentation of the NH2-terminal domain of ezrin with PIP2-
containing liposomes. The cosedimentation of ezrin domains,
with or without the GST moiety (55 mg protein/ml), with large li-
posomes containing 20% PIP2 and 80% PC (0.5 mg lipid/ml) in
the presence of 130 mM KCl was determined as described in Ma-
terials and Methods. n.d., not done; n.a., not applicable.The Journal of Cell Biology, Volume 151, 2000 1070
Progressive deletions from the COOH terminus of ezrin
1-333 illustrated the importance of amino acids 233–310 in
the assay of cosedimentation with liposomes (95 6 8% in-
hibition of cosedimentation for ezrin 1-233, n 5 4; Fig. 1).
The internal deletion of residues 13–114 also led to a dra-
matic loss of the resulting construct to interact with lipo-
somes (89 6 18% inhibition, n 5 3). GST alone did not
cosediment with the liposomes and elimination of the GST
moiety did not affect association with PIP2-containing li-
posomes (Fig. 1). This finding shows that unspecific trap-
ping of protein in the lipid pellet is negligible under our
experimental conditions. The results shown in Fig. 1 also
demonstrate that ezrin 1-333 is capable of recruiting a pro-
tein incapable of membrane interaction (GST) to the bi-
layer. The PIP2 binding domain of ezrin therefore appears
to consist of nonlinear determinants and involves distinct
portions of the molecule.
By analogy with several PIP2-binding proteins and pleck-
strin homology (PH) domains, it was inferred that a number
of basic residues could be involved in such an interaction.
Typical PIP2-binding motifs consist of clusters of basic
amino acids; e.g., (K/R)XXXKX(K/R)(K/R) in gelsolin or
(K/R)XXXX(K/R)(KR) in villin (Janmey et al., 1992; Yu et
al., 1992). Two similar motifs are conserved in the entire
ERM family at identical positions and also at comparable
positions in merlin, if one takes into account the extended
NH2 terminus of merlin (Fig. 2). A third motif (RXRXXRR)
as well as a cluster of basic amino acids (RRRK) are present
in the ERM family at positions 273–279 and 293–296, re-
spectively. However, we demonstrate below that the two
motifs shown in Fig. 2 are crucial for PIP2 interaction. Inter-
estingly, one of these motifs was present in the 234–309 re-
gion and one in the 13–114 portion of the molecule, the two
regions identified by truncation experiments as important
for PIP2 interaction. As shown in Fig. 1, interaction with
PIP2-containing liposomes was abolished when either of
these regions was deleted. The COOH-terminal domain of
ezrin also contains regions with clusters of basic amino ac-
ids. However, we have shown previously that this domain
does not significantly interact with PIP2-containing lipo-
somes (Niggli et al., 1995). These motifs thus are not func-
tionally relevant for lipid interaction.
Site-directed Mutagenesis of Potential PIP2
Binding Sites
Several double mutations of the lysine residues located in
the presumed motifs were introduced in the ezrin 1-333
molecule. As shown in Table I, double mutations of either
lysines 253 and 254, or lysines 262 and 263 to asparagine did
not significantly impair the ability of the mutated construct
to cosediment with PIP2-containing liposomes. The double
substitution K63N, K64N by contrast led to a significant
(P  ,  0.025) partial reduction in the amount of mutated
ezrin 1-333 that cosedimented suggesting a particularly im-
portant role of these residues (Table I). The combination of
the K253N, K254N and the K262N, K263N mutations led to
an almost complete loss of interaction with PIP2 (84 6 11%
inhibition, n 5 6). The combination of K63N, K64N and
K253N, K254N mutations resulted similarly in a protein
with strongly reduced PIP2-binding capacity (78 6 11% in-
hibition, n 5 3), far exceeding the effect of the double mu-
tation of K63N, K64N alone. The introduction of the
K262N, K263N mutations into this mutant did not further
reduce binding. For optimal binding, the presence of either
Figure 2. Potential PIP2 binding sites in the ERM family. Se-
quences were obtained from the Swiss Protein data bank. Acces-
sion numbers are: ezrin, P15311; radixin, P35241; moesin, P26038;
and merlin, P35240.
Table I. Effects of K to N Mutations on Cosedimentation of 
Ezrin 1-133 with PIP2-containing Liposomes
Mutations K . N introduced in positions:
Percent protein
in pellet n 63 and 64 253 and 254 262 and 263
22 2 59 6 13 11
12 2 27 6 43
11 29  6 23
21 2 61  6 12 6
22 1 48 6 18 6
21 16 6 46
11 1 10  6 53
Wild type and mutant ezrin 1-333 domains (27.5–55 mg protein/ml) were incubated in
the presence of 100 mM NaCl and in the absence or presence of large liposomes
containing 20% PIP2 and 80% PC (0.5 mg lipid/ml), followed by determination of the
fraction of liposome-associated protein, as described in Materials and Methods. Mean 6
SD of n experiments.
Figure 3. Cosedimentation of wild-type and mutant ezrin 1-333
with large liposomes containing different amounts of PIP2. Wild-
type (WT) and mutant ezrin domains (55 mg protein/ml) were in-
cubated in the presence of 100 mM NaCl and in the absence or
presence of large liposomes containing 5, 10, or 20% of PIP2, the
remainder being PC (0.5 mg lipid/ml). The fraction of cosedi-
menting protein was assessed as described in Materials and
Methods. Mean 6 SD of three to eight experiments.Barret et al. Phosphatidylinositol 4,5-Bisphosphate Binding Determinants in Ezrin 1071
Figure 4. The mutations introduced specifically target ezrin-PIP2 interactions. (A) Introduction of four K . N mutations in ezrin did
not change the chymotrypsin digestion pattern. Wild-type (WT) and mutated ezrin 1-586 (K253N, K254N, K262N, and K263N) (285 mg/
ml) were incubated in the presence or absence of 3.3 mg/ml chymotrypsin at room temperature for the indicated times. After SDS-
PAGE, membranes were immunoblotted with a polyclonal antibody targeted against the first 310 amino acids of ezrin. No major differ-
ence in the digestion patterns was observed when wild-type or mutated ezrin were compared. (B) Introduction of four K . N mutations
in ezrin (K253N, K254N, K262N, and K263N) did not alter F-actin binding. F-actin binding was measured using a solid phase assay as
described by Roy et al. (1997). Actin concentrations were chosen so that they were below, around, and above the dissociation constant
(500 nM) for actin binding to ezrin. For each actin concentration, binding was measured in the presence or absence of PIP2. Bound actin
was detected using a monoclonal anti-actin antibody. The top two blots illustrate the binding of actin to the NH2-terminal domain of
wild-type and mutant ezrin (residues 1–333). The bottom two blots correspond to actin binding to full-length ezrin with or without the
four K . N mutations. No obvious difference in F-actin binding capacity was observed when comparing mutated ezrin constructs with
their parent wild-type counterparts. (C) Mutagenesis of the PIP2 binding site in ezrin 1-333 did not impair the interaction of the NH2-
terminal domain of ezrin with the cytoplasmic tail of EBP50. The binding of wild-type ezrin 1-333 (WT and *) or mutated ezrin 1-333
(mutated and **) (1 mM) to GST-EBP 50 or GST was assessed as described for binding to CD44 in Materials and Methods. (Top) Coo-
massie staining, (bottom) Western blotting. The experiment had been done in triplicate for each construct. Western blotting showed
that there was no major difference between WT ezrin 1-333 and the mutated form concerning binding to GST-EBP50. The right two
lanes demonstrate the lack of binding of ezrin 1-333 WT (*) or mutated (**) when assayed with the control GST free of fusion protein.
(D) Introduction of up to six K . N mutations in ezrin did not affect homotypic interactions. Wild-type ezrin 1-586 was coated in wells
of a microtiter plate (Roy et al., 1997). Ezrin 1-333 constructs (0.5 mM each) were then added in F-actin buffer, except for the first lane,
where no construct was added (*). Similar amounts of ezrin 1-586 were coated in each well as judged by the Coomassie stain of the top
blot. The same polyclonal anti-ezrin antibody as in A was used to detect the construct overlaid and, irrespective of the mutations intro-
duced, no major difference in the amount of ezrin 1-333 construct bound to ezrin 1-586 was observed (bottom). When no ezrin 1-586
was coated, no ezrin 1-333 was detectable (not shown). (E) Intrinsic tryptophane fluorescence was not modified upon introduction of
four K . N mutations in full-length ezrin. (Top curve) Full-length mutated ezrin K253N, K254N, K262N, and K263N; (bottom curve)
wild-type ezrin 1-586. Note that neither the maximum intensity of tryptophane fluorescence nor the wavelength for maximum emission
were significantly affected upon introduction of the four mutations.The Journal of Cell Biology, Volume 151, 2000 1072
lysines 63, 64, 253, and 254 or lysines 253, 254, 262, and 263
is thus required. The presence of lysines 63 and 64 alone is
not sufficient to maintain binding, correlating with the ex-
periments on the truncated NH2 terminus (Fig. 1).
The finding that some double mutations (K253N,
K254N or K262N, K263N) did not significantly alter PIP2
binding of ezrin 1-333 could be due to the use of saturating
amounts of PIP2 in the liposomes, which may not allow us
to detect subtle changes in lipid binding. According to our
previous findings, the interaction of full-length wild-type
ezrin with liposomes is maximal at 20% PIP2 and 80% PC
(Niggli et al., 1995). We therefore compared interactions
of mutated and wild-type proteins with liposomes contain-
ing lower amounts of PIP2. As shown in Fig. 3, at 10 and
5% PIP2, no statistically significant difference was detect-
able between cosedimentation of mutants ezrin 1-333
K253N, K254N, ezrin 1-333 K262N, K263N, and the wild-
type form of ezrin 1-333.
Since the serine 66 residue corresponds to a potential
protein kinase A phosphorylation site, we performed a
S66D mutation in ezrin 1-333 to analyze the effects of in-
troducing a negative charge next to the neighboring lysine
residues involved in PIP2 binding. However, the S66D mu-
tant behaved as the wild-type domain (not shown). Intro-
duction of a negative charge next to lysines 63 and 64 thus
does not disturb PIP2 binding.
On the basis of the findings summarized in Fig. 1 and Table
I, the full-length ezrin molecule was mutated in positions 253,
254, 262, and 263 and in combination with positions 63 and
64. The amount of mutated construct recovered in the lipo-
some-containing pellet corresponded to 2% of total protein
for K253N, K254N, K262N, and K263N and to 3% for K63N,
K64N, K253N, K254N, K262N, and K263N, as compared
with 24% of wild-type ezrin cosedimenting with liposomes
(n 5 2). PIP2 interaction of these two mutants was thus al-
most completely abolished, corresponding to the findings
with the 1-333 constructs.
Conformation and Functional Properties of
Mutated Ezrin
To exclude that our findings were due to an unstable folding
and/or overall denaturation of the mutated protein, we com-
pared the sensitivity of wild-type ezrin and ezrin K253N,
K254N, K262N, and K263N to chymotrypsin (Fig. 4 A).
Chymotrypsin has been previously used to partially proteo-
lyze ezrin and identify a chymotryptic-resistant NH2-termi-
nal domain (Franck et al., 1993; Niggli et al., 1995). No ma-
jor differences in the degradation patterns were observed
when ezrin was mutated: the 35- and 24-kD bands detected
with an antibody directed against the first 310 amino acids of
ezrin were the major degradation products for both the
wild-type and the mutated ezrin, indicating therefore that
both molecules were similarly folded (Fig. 4 A). However,
the 24-kD degradation product appeared earlier with ezrin
K253N, K254N, K262N, and K263N, suggesting that its fold-
ing was less stable than that of wild-type ezrin.
The same mutations also did not alter the ability of the full-
length ezrin molecule nor that of the ezrin 1-333 construct to
bind to F-actin at relatively high concentrations (0.5–2.5 mM
F-actin) as measured in the solid phase assay (Fig. 4 B) (Roy
et al., 1997). Under more stringent conditions (0.1 mM
F-actin), the binding capacity of mutated molecules may be
lowered. The addition of PIP2 was without effect on the F-actin
binding of both constructs whether they were mutated or not,
emphasizing therefore the lack of requirement for PIP2 to
bind to F-actin under our assay conditions. The K253N,
K254N, K262N, and K263N ezrin 1-333 also interacted with
the cytoplasmic tail (amino acids 329–358) of EBP 50 in fu-
sion with GST to the same extent as wild-type ezrin 1-333
(Fig. 4 C). No interaction with control GST was detectable.
Figure 5. Mutagenesis of the PIP2 binding site in ezrin results in a
loss of PIP2 requirement of the interaction of ezrin with the cyto-
plasmic tail of CD44. Binding of full-length wild-type ezrin or ezrin
K253N, K254N, K262N, and K263N (K253,254,262,263N) to GST
or GST-CD44 in the absence or presence of PIP2 was assessed as
described in Materials and Methods. Aliquots of the supernatant
were then analyzed by SDS-PAGE and immunoblotted for the
presence of ezrin. (A) Coomassie blue staining of the blots shows
that comparable amounts of GST-CD44 (or GST) were detected
in all lanes (top, incubation with GST-CD44 beads; bottom, incu-
bation with GST beads). In contrast to wild-type (WT) ezrin (top
left), K253N, K254N, K262N, and K263N (K253,254,262,263N)
mutations in ezrin induced constitutive binding to GST-CD44–
coupled agarose beads independently of the addition of PIP2 mi-
celles (top right). GST beads alone (bottom) were used as control.
During the GST-CD44 preparation, significant cleavage of the fu-
sion protein occurred, resulting in large amount of GST adsorbed
on the gel. (B) The amount of wild-type or mutated ezrin bound to
GST-CD44 or to GST alone was quantified by densitometry of the
immunoblots shown in A. Black and hatched columns represent
ezrin bound to GST and GST-CD44, respectively. The results
shown are representative of three independent experiments.Barret et al. Phosphatidylinositol 4,5-Bisphosphate Binding Determinants in Ezrin 1073
Figure 6. Mutated ezrin loses its cell membrane localization in transfected A431 and COS1 cells. Human adenocarcinoma A431 epithe-
lioid cells (a–f) and monkey kidney COS1 fibroblasts (g–l) were transfected with either VSV-G–tagged wild-type ezrin (a–c and g–i) or
mutated ezrin (K253N, K254N, K262N, and K263N) (d–f and j–l) DNA and treated for indirect Texas red localization of ezrin with
anti–VSV antibody (left) and F-actin with FITC-coupled phalloidin (middle). Pictures represent the projected maximum intensities of
several focal planes ranging from substrate to apical level, except for d and j. Vertical xz sections at the level of the dotted lines are un-
der each figure. Insets are enlargements of the squared areas in a–c. Dual localizations of ezrin and actin are merged in color, colocaliza-
tion appearing in yellow. Transfected wild-type ezrin is located in actin-rich cell surface structures such as microspikes, dorsal microvilli
(a–c, circles) or ruffles (g–i, arrows), and in lateral cell membranes (a and c, intercellular contacts). Note that focal adhesion plaques (b,
c, e, and f, insets, arrowheads) and stress fibers (k) are devoid of any ezrin. Transfected mutated ezrin is essentially located as a cytosolic
network (d, f, j, and l; note that single focal planes are used only in d and j for clearer visualization of ezrin), but is also faintly detectable
on the cell membranes in COS1 cells (j, arrow). Localization of wild-type ezrin in actin-rich dorsal structures and mutated ezrin in cyto-
plasm is evident in xz sections. Bars, 10 mm.The Journal of Cell Biology, Volume 151, 2000 1074
Using the solid phase assay, we demonstrated that the
three pair mutations (K . N; residues 63 and 64, 253 and
254, and 262 and 263) introduced in ezrin 1-333, either
alone or in combination, did not impair its homotypic as-
sociation with the full-length molecule (Fig. 4 D).
In addition, the intrinsic tryptophane fluorescence spectra
of both wild-type ezrin and mutated molecule were similar
upon normalization and exhibited identical maximum wave-
length emission (Fig. 4 E). The 10% difference observed in
the maximum intensity may be due to an overestimation of
the protein concentration of wild-type ezrin, but in no case
did the tryptophane fluorescence of the mutated ezrin appear
to be significantly quenched upon exposure of trytophane(s)
to solvent due to an inappropriate folding of the molecule.
Overall, the differences in the properties of wild-type
and mutated ezrin documented in Fig. 4 are all very small,
whereas the effects of the mutations on PIP2 binding were
drastic. The overall conformation of the ezrin molecule as
well as some of its major functional binding properties ap-
peared to be essentially preserved after introducing these
mutations, except for its ability to interact with PIP2-con-
taining liposomes.
Alteration of the PIP2-dependent
Ezrin-CD44 Interaction
The interaction of ezrin with CD44 has been demon-
strated to be PIP2-dependent under physiological ionic
strength conditions (Hirao et al., 1996). We therefore
tested whether mutations in the residues involved in PIP2
binding affected ezrin interaction with the cytoplasmic tail
of CD44 in vitro. Indeed in the presence of PIP2 micelles,
the amount of wild-type ezrin binding to GST-CD44 im-
mobilized on glutathione agarose beads was significantly
increased (Fig. 5). In contrast, the binding of ezrin K253N,
K254N, K262N, and K263N to the same beads was unaf-
fected by PIP2 addition, and was already comparable with
the level obtained with wild-type ezrin in the presence of
PIP2. As a control, both the wild-type and mutated forms
of ezrin did not bind to GST-glutathione agarose beads, ir-
respective of the presence of PIP2 (Fig. 5).
Abnormal Localization of Ezrin Deficient in
PIP2 Binding
A431 epithelial cells and COS1 fibroblasts were trans-
fected with ezrin K253N, K254N, K262N, and K263N or
with wild-type ezrin, both constructs being tagged with
VSV-G epitope. In A431 cells, wild-type ezrin VSV-G
colocalized with F-actin at apical ruffles and microvilli,
plasma membranes, and microspikes, as already described
for endogenous ezrin (Gould et al., 1986; Algrain et al.,
1993). Stress fibers and adhesive plaques were decorated
with actin but not with ezrin (Fig. 6, a–c and g–i). On the
contrary, in A431 and COS1 cells, mutated ezrin VSV-G
was found to be located as a sponge-like network within
the cytoplasm, clearly visible on single focal planes (Fig. 6,
d and j) and xz sections. Mutated ezrin was only faintly de-
tectable at the leading edge of plasma membranes or mi-
crospikes (Fig. 6 j). Clearly, mutated ezrin VSV-G labeling
was excluded from vesicular structures. Expression of this
mutated form of ezrin, however, did not alter cell size and
morphology or actin-rich structures.
The subcellular distribution of wild-type and K253N,
K254N, K262N, and K263N VSV-G–tagged ezrin was
compared upon cell fractionation of COS1 cells. No
marked difference was observed in partition of these pro-
teins between cytosol and total membrane fractions (Fig. 7
A). However, the amount of Triton X-100 insoluble ezrin
associated with the cytoskeleton was significantly lower
in the case of mutated ezrin (37% of total cellular ezrin
VSV-G vs. 27% of K253N, K254N, K262N, and K263N
ezrin VSV-G; Fig. 7 A). As pointed out for actin, the dis-
tribution of endogenous ezrin was not significantly af-
fected by expression of either form of ezrin VSV-G.
Loss of the Cell Extension Activity of the NH2-Terminal 
Domain of Ezrin Upon Mutation of Its PIP2
Binding Domain
COS1 fibroblasts were also transfected with the VSV-
G–tagged NH2-terminal domain of either wild-type or mu-
tated ezrin. As previously described (Martin et al., 1997),
Figure 7. Subcellular localization of transfected mutated and
wild-type ezrin in COS1 cells. Transfected cells were fractionated
as described in Materials and Methods and the resulting fractions
were analyzed by SDS-PAGE and immunoblotting. Before im-
munodecoration, blots were stained with Coomassie blue to en-
sure that protein loadings were comparable. (A) Transfection of
full-length ezrin. Transfected VSV-tagged wild-type and K253N,
K254N, K262N, and K263N (K253,254,262,263N) ezrin were re-
covered in cytosol (C), Triton X-100 extractable (E), or nonex-
tractable (N) material, as revealed after immunoblotting with
anti–VSV-G mAb. Anti-ezrin antibody, which recognizes both
endogenous and VSV-G–tagged ezrin, was used as a control
(top). *Internal control with recombinant wild-type ezrin (100 ng
load). Results shown are representative of three independent ex-
periments. (B) Transfection of ezrin 1-310. Detection of the top
blot was performed with an antibody against the NH2-terminal
portion of ezrin. The proportion of cytosolic full-length ezrin (#)
detected with this antibody is lower than that presented in A due
to the poor accessibility of the anti–N antibody to the epitopes in
the full-length ezrin. Note that some degradation of ezrin was de-
tectable in the nonextractable material (N). Immunodetection of
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Figure 8. The mutated NH2-terminal
domain of ezrin partly loses its interac-
tions with membranes. Monkey COS1
fibroblasts were transfected with either
VSV-G–tagged wild-type (a–c) or mu-
tated (K253N, K254N, K262N, and
K263N) (d–f) ezrin 1-310 and treated
for immunolocalization of actin (b and
e) and VSV (a and d) as in Fig. 6.
Transfected wild-type NH2-terminal
ezrin was mainly localized in actin-rich
structures such as dorsal microvilli and
ruffles (b and c, arrows; xz sections, cir-
cles). It induces formation of long
filopodia containing both actin (b and
c, arrowheads) and transfected ezrin (a
and c, arrowheads). Note the presence
of nodes along filopodia, particularly
rich in NH2-terminal ezrin (open ar-
rows). The transfected mutated form
of NH2-terminal ezrin was predomi-
nantly localized in the cytoplasm (d
and f), although some mutant ezrin lo-
calized in the same actin-rich structures
(e and f) as wild-type NH2-terminal
ezrin. Staining of nuclei was observed
only in cells transfected with mutated
ezrin 1-310 (d and f). Bars, 10 mm.
Figure 9. Location of the targeted lysines in moesin. The crystallo-
graphic data of moesin were treated with the molecular visualiza-
tion program RASMOL (R. Sayle, Glaxo Wellcome, Greenford,
UK). (A) The different domains of the molecule defined by Pear-
son et al. (2000) were colored as follows: residues 4–94, violet (do-
main FI); residues 95–201, blue (domain F2); residues 202–297,
green (domain F3); and residues 488–577, red (COOH-terminal
domain). The lysines of interest have been highlighted in yellow.
The distances between the epsilon NH2 of lysines 63–262, 63–254,
and 254–263 are equal to 38.1, 27.6, and 19 Å, respectively. Note
that all these lysines are accessible to solvent and therefore to PIP2.
They are all located on the same side of the molecule. (B) Moesin
residues that may be in direct contact with the bilayer. Using RAS-
MOL, residues exposed on the surface of moesin and enclosed by
the triangle formed by lysines 63, 64, 253, 254, 262, and 263 (bold
and underlined) have been identified (bold).The Journal of Cell Biology, Volume 151, 2000 1076
the transfection of the 1–310 fragment of ezrin induced
formation of long filopodia, which contain both tagged
ezrin 1-310 and actin (Fig. 8, a–c). This cell extension activ-
ity of the ezrin NH2-terminal domain is dependent on the
cell type used and was not observed in the case of CV1
cells (Algrain et al., 1993). Ezrin 1-310 and actin colocal-
ized to a variable extent along these structures. Trans-
fected ezrin 1-310 was also localized in actin-containing
structures such as surface microvilli, dorsal ruffles, and lat-
eral microspikes, comparable with the wild-type full-
length molecule. Possibly due to its overexpression, tagged
ezrin 1-310 was regularly observed in the cytoplasm and
was excluded from vesicles. Strikingly, upon transfection
of the cells with mutated ezrin 1-310, almost no cell exten-
sions developed and the cells were extremely flattened.
The localization of the mutated form of NH2-terminal do-
main of ezrin appeared essentially cytoplasmic even if co-
labeling of some extensions containing actin persisted
(Fig. 8, d–f). Note that with this construct some staining of
the nucleoli was apparent (see Discussion). Upon cell frac-
tionation, wild-type ezrin and mutated ezrin 1-310 were re-
covered in the particulate fraction (Fig. 7 B). At variance
with the microscopic observations, no ezrin 1-310 was re-
covered in the cytosolic fraction. This discrepancy can be
explained with the relative insolubility of the NH2-termi-
nal domains of ezrin, especially in low salt buffers such as
those used for cell lysis.
Discussion
PIP2, a lipid whose turnover is modified upon cell activa-
tion, has been implicated in the regulation of the functions
of a number of cytoskeletal proteins (Janmey, 1995; Isen-
berg and Niggli, 1998). Depending on the protein studied,
PIP2 interactions may concentrate proteins at the plasma
membrane in a manner affected by cell activation, possibly
within PIP2-enriched domains (Martin, 1998). PIP2 may
also modulate the function of the protein to which it binds
(Gascard et al., 1993; Huttelmaier et al., 1998; Steimle et
al., 1999). Knowledge of the molecular determinants in-
volved in lipid–protein interactions is a prerequisite for
studying their physiological role in intact cells. We have
therefore analyzed the nature of PIP2-binding determi-
nants in ezrin by truncations, internal deletion, and site-
directed mutagenesis. PIP2 binding was studied using large
liposomes containing 20% PIP2 and 80% PC, in physiolog-
ical salt concentrations. Presenting PIP2 in mixed bilayers
is much closer to the cellular environmental conditions
than presentation as micelles of pure lipid. The advantage
of the cosedimentation assays is also that free ezrin is al-
ways exposed to the bilayer and never separated during
the assay. A disadvantage is that it cannot be completely
excluded, that ezrin extracts some PIP2 molecules to form
a small complex that does not sediment. As previously
shown, binding of full-length ezrin is maximal at z20%
PIP2, and 5–10% of PIP2 still induced significant associa-
tion (Niggli et al., 1995). This is similarly the case for wild-
type ezrin 1-333 (Fig. 3).
We first showed, by progressive truncations and internal
deletions, that the NH2 terminus of ezrin contains two do-
mains essential for PIP2 binding, located in regions 12–115
and 233–310. The loss of one of the sites resulted in almost
complete loss of binding. Interestingly, recent findings for
gelsolin similarly suggest that this protein binds to PIP2-
containing bilayers via a site formed by the juxtaposition of
the NH2- and COOH-terminal domains of gelsolin (Tuom-
inen et al., 1999). To our knowledge, these are so far the
only two proteins known with a pair of PIP2-binding sites.
Inspection of the sequence of the NH2-terminal domain
of ezrin revealed two potential PIP2 binding motifs, which
are similar to the motifs identified in gelsolin and villin
(Fig. 2). We have analyzed the role of these motifs in
ezrin-PIP2 binding by mutation of selected lysines to as-
paragines. These experiments revealed an important role
of lysines 63 and 64, which are required for optimal bind-
ing. In contrast, two independent double mutations of
lysines 253 and 254 or 262 and 263 to asparagines were of
no consequence for the interaction with PIP2. However,
this does not mean that they are not involved in binding
since mutation of all four lysines 253, 254, 262, and 263 re-
sulted in an almost complete loss of binding similar to that
observed after mutation of lysines 63, 64, 253, and 254.
The presence of the lysines in the 63–72 motif is thus
clearly necessary, but not sufficient for interaction. This
conclusion is supported also by the inability of fragment
1–233 to bind to PIP2. For optimal binding, the combined
presence of K63, K64, K253, and K254 or K253, K254,
K262, and K263 is thus required. Our results suggest that
the two domains located in regions 63–72 and 253–263 do
cooperate in PIP2 binding. The site at amino acids 63–72
corresponds to a KKXXXXXX(K/R)K motif, which is
similar to, but not identical with, the consensus sequence
in villin, (K/R)XXXX(K/R)(K/R) (Yu et al., 1992). The
site at amino acids 253–263, a KKXXXKXXXKK mo-
tif resembles a consensus sequence for gelsolin, (K/
R)XXXKX(K/R)(K/R) (Yu et al., 1992). Typically, the
motifs involved in ezrin–PIP2 interaction start and end
with two basic amino acids, whereas the sites in gelsolin
and villin start with only one lysine or arginine. In addi-
tion, the numbers of interspersed amino acids are different
in ezrin. Another motif has been detected in the cytoskele-
tal protein a-actinin, and also in spectrin and the PH do-
main of phospholipase C-d1 and Grb7: RXXXXXXX(H/
RK)XX(X)W(K/R) (Fukami et al., 1996). Again, this mo-
tif is not identical with those detected in ezrin.
During the completion of this manuscript, the crystal
structure of a complex of the NH2-terminal domain of
moesin (residues 1–297) with the tail (residues 467–577)
has been published (Pearson et al., 2000). According to
this work, residues 63, 64, 253, 254, 262, and 263 are all lo-
cated in loops connecting b sheets. In a space-filling model
of moesin, the residues implicated in PIP2 binding are all
located on the surface of the molecule (Fig. 9 A). The resi-
dues form a triangle (Fig. 9 A). The surface enclosed by
this triangle is relatively planar, so that a simultaneous
contact of all residues with several PIP2 molecules in a bi-
layer appears to be feasible. The residues enclosed by this
triangle and exposed on the surface of moesin have been
highlighted in the moesin sequence (Fig. 9 B). These resi-
dues, which could form a zone of contact with a PIP2-con-
taining bilayer, are identical in moesin and ezrin, with the
exception of asparagine 62 in moesin, which corresponds
to aspartic acid 62 in ezrin. Of these residues, including the
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16% are negatively charged, 24% are uncharged but polar,
and 24% are hydrophobic. Interestingly, Pearson et al.
(2000) detected a hitherto unrecognized PH-like domain
in the structural module F3 of moesin, where residues 253,
254, 262, and 263 are located. Such PH domains are in-
volved in phosphoinositide binding and feature an antipar-
allel b sheet consisting of seven strands and a COOH-ter-
minal a-helix (Harlan et al., 1995), comparable with the
structure of F3 of moesin. Using the web-based tool
SMART (Simple Molecular Architecture Research Tool;
Schultz et al., 1998), we searched for a PH domain in the
NH2-terminal domain of ezrin, but were unsuccessful. If
F3 indeed corresponds to a functional PH domain, then
the distribution of charged amino acids is not typical for
such domains. According to Pearson et al. (2000), the
highly positively charged surface of lobe F3 of moesin may
be suitable for binding of negatively charged phospholip-
ids, in agreement with our results. Based on the crystalliza-
tion results, the PIP2 binding domain in ezrin is thus also
different from the lipid-binding domain identified in vin-
culin, which has been shown to form an amphipathic heli-
cal hairpin (Johnson et al., 1998). Ezrin appears to contain
two structural elements cooperating in PIP2 binding and
one of these elements may be part of a PH domain. These
two domains do not appear to be directly involved in F-actin
binding, nor do these mutations affect a distal F-actin
binding site, as F-actin interaction of ezrin K253N, K254N,
K262N, and K263N was not altered. A similar conclusion
can be drawn for the interaction of ezrin with EBP 50.
It is unlikely that the effects reported in this paper on
ezrin–PIP2 interaction could be simply due to an overall
change of the positive charges of the protein. For example,
the double mutation K63N, K64N significantly decreased
PIP2 binding, whereas the two double mutations of lysines
to asparagines at positions 253 and 254 or 262 and 263 had
no significant effects. At pH 7.4, the calculated net global
charge for the wild-type protein is 16.26 (ezrin 1-333) and
28.34 (ezrin 1-586). Introducing six K . N mutations
yielded global charges that were 10.27 and 214.34. In
spite of the net charge difference between ezrin 1-333 and
full-length ezrin, the very same PIP2-binding determinants
were found to be important in the two molecules. More-
over, experiments were carried out under physiological
ionic strength conditions. Under these conditions, the
range of distances where electrostatics overcome thermal
energies is relatively small, and the precise positioning of
specific basic amino acids, rather than the overall charge
of the NH2-terminal domain, is likely to be important for
ezrin–PIP2 interaction. For example, the PH domain of
pleckstrin is electrically polarized (Blomberg and Nilges,
1997), and mutation of three conserved lysine residues in
this domain has been shown to result in 10-fold decrease in
lipid-binding affinity (Harlan et al., 1995). As outlined for
the PH domain, other determinants for PIP2 interaction,
based, for example, on interactions with acyl chains of the
lipid, exist and may account for a pronounced, albeit in-
complete, loss in affinity as described in the case of the
mutated PH domain of pleckstrin (Harlan et al., 1995).
Interestingly, the introduction of two double mutations
(K253N, K254N and K262N, K263N) results in the loss of
PIP2 requirement for optimal binding of ezrin to the cyto-
plasmic tail of CD44. As shown in Fig. 5, the binding be-
tween CD44 and the mutated form of ezrin is not impaired
but becomes PIP2 independent. This portion of the CD44
molecule contains clusters of basic amino acids involved in
the CD44/ezrin interaction (Legg and Isacke, 1998). PIP2
may neutralize basic residues in ezrin, resulting in elimina-
tion of repulsive forces between the two molecules. Intro-
ducing the mutations may generate the same effect. How-
ever, using truncation experiments, Yonemura et al.
(1998) demonstrated that the first 19 residues of the cyto-
plasmic tail of CD44, containing a cluster of basic residues,
were sufficient, at physiological ionic strength, to allow
ERM-CD44 interactions, whereas binding of the full-
length cytoplasmic tail was markedly reduced under these
conditions. These interactions were studied in the absence
of PIP2. This finding cannot be reconciled with the hypoth-
esis that charge neutralization by lipid is required for such
a protein interaction to occur.
Wild-type VSV-G–tagged ezrin is massively recruited to
dorsal actin-rich structures. The K253N, K254N, K262N,
and K263N mutated form of ezrin was introduced into
both epithelioid and fibroblastic cell lines. Immunofluo-
rescence localization showed that the VSV-G–tagged mu-
tant was now mainly located in the cytoplasm, without
colocalization with F-actin and only weak binding to
plasma membranes. Based on our in vitro findings, one
would expect that mutated ezrin would bind to plasma
membrane proteins independently of PIP2. In fact, Legg
and Isacke (1998) concluded, using CD44-negative cells,
that the localization of ezrin to microvilli was not medi-
ated through an interaction with CD44, but rather with
other sites at which the actin network closely associated
with the plasma membrane. In our study, mutated ezrin
expressed in cells no longer localizes to microvilli and ruf-
fles, suggesting that a direct PIP2–ezrin interaction may be
one of the necessary events to address ezrin to these spe-
cific membrane structures. Since ERM proteins are in-
volved in the formation of the very same structures, the cy-
toplasmic localization of the mutated ezrin protein might
simply result from an upstream defect (PIP2 binding) ab-
solutely required for the formation of a novel ezrin-con-
taining membrane structure. Cell fractionation studies
showed indeed that recovery of the mutated ezrin in the
cytoskeleton-associated membrane fraction was signifi-
cantly reduced as compared with the wild-type protein,
supporting the immunofluorescence studies. However, to-
tal recovery in the membrane fraction appeared not to be
altered. This may be due to redistribution occurring during
the isolation procedure using detergent.
It has been suggested that multimeric forms of ezrin are
involved in the generation of actin-rich structures (Gary
and Bretscher, 1993). Interactions between NH2-terminal
domains of ERM proteins and full-length proteins result-
ing in multimer formation have been shown to interfere
with the normal functions of endogenous proteins in the
NIH3T3 cell line (Henry et al., 1995; Amieva et al., 1999).
Using a solid phase assay, we found that wild type as well as
mutated ezrin 1-333 and full-length ezrin engaged in homo-
typic interactions (Fig. 4 D). However, by immunolocaliza-
tion, no mutated ezrin was found associated with actin-rich
structures. We can thus conclude that the formation of het-
erodimers of wild-type and mutated ezrin is not sufficient
for the association with actin-containing domains.The Journal of Cell Biology, Volume 151, 2000 1078
A number of reasons led us to transfect cells with the
whole NH2-terminal domain of ezrin (residues 1–310)
rather than the portion of the protein containing the PIP2
binding determinants (residues 63–263). Amino acids be-
yond 296 are necessary for engaging in homotypic as well
as heterotypic interactions (Gary and Bretscher, 1993).
Deletion of amino acids 13–30 in ezrin (Martin et al., 1997)
or of the first 11 residues of moesin (Amieva et al., 1999)
led to drastic changes of the localization of the NH2-termi-
nal portion of these proteins. Ezrin 1-320 still localizes
to the membrane, whereas fragment 1-276 is cytosolic
(Amieva et al., 1999). Thus, deleting any of these portions
of the molecule may be dominant over the mutations of
the PIP2 binding determinants. In fact, introduction of the
latter mutations led to an expression pattern similar to the
one observed for any of the deletions described above.
These observations suggest that any change in the NH2-
terminal domain of the ERM can drastically affect the
protein structure and/or function. Of interest is the obser-
vation that when the PIP2 binding determinants were mu-
tated, the NH2-terminal domain of ezrin localized within
the nucleoli. Although the possibility of an artifact has to
be considered, a 55-kD ezrin-related protein that cross-
reacts with antibodies against the NH2-terminal domain of
ezrin has been detected in the nucleus of many human
transformed cells (Kaul et al., 1999). Evidence has also
been presented for the nuclear localization of isoforms of
protein 4.1, the first member of the ERM family (Correas,
1991). In this latter case, at variance with our observations,
a cluster of basic residues was necessary for such a local-
ization to occur (Luque et al., 1998).
In conclusion, two PIP2 binding determinants exist in
ezrin in regions 12-115 and 233-310 of the protein, with
lysines 63, 64, 253, 254, 262, and 263 playing a major role
for efficient interaction. As these residues are conserved in
the ERM family (Fig. 2), ezrin, moesin, and radixin may
specifically bind to PIP2 using the same determinants. Al-
though we cannot exclude the possibility that the muta-
tions described in this work alter other functions of ezrin,
these mutated residues are likely candidates involved in
the targeting of ezrin to, and presumably in the formation
of, F-actin–rich membrane structures.
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